Security key
71880W501
Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO)
CUSIP: 71880W501
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 12,067,869
- Total 13F shares
- 164,722
- Share change
- +64,104
- Total reported value
- $387,355
- Price per share
- $2.35
- Number of holders
- 11
- Value change
- +$164,978
- Number of buys
- 7
- Number of sells
- 4
Report period
Q2 2025
Institutions
11
Top holders
10
PHIO full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Phio Pharmaceuticals Corp. SEC filings
Phio Pharmaceuticals Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 71880W501
Recent filing periods:
Top shareholders of PHIO - Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.34%
|
41,586
|
$54,060 | — | 31 Mar 2025 | |
| Cetera Investment Advisers |
13F
|
Company |
0.32%
|
38,500
|
$50,050 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.09%
|
10,800
|
$14,040 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.05%
|
6,000
|
$7,800 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
2,501
|
$3,251 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.01%
|
968
|
$1,258 | — | 31 Mar 2025 | |
| ASSETMARK, INC |
13F
|
Company |
0%
|
110
|
$143 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
103
|
$134 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
41
|
$53 | — | 31 Mar 2025 | |
| Activest Wealth Management |
13F
|
Company |
0%
|
9
|
$12 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
5
|
$7 | — | 31 Mar 2025 | |
| Gerrit Dispersyn |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
212,327
|
$320,614 | — | 01 Mar 2022 | |
| H. Paul Dorman |
3/4/5
|
Director |
—
class O/S missing
|
20,370
|
$30,759 | — | 15 Feb 2022 | |
| Caitlin Kontulis |
3/4/5
|
Secretary & VP Finance & Admin |
—
class O/S missing
|
10,643
|
$10,196 | — | 01 Mar 2024 | |
| Robert M. Infarinato |
3/4/5
|
VP, CFO |
—
class O/S missing
|
11,000
|
$8,140 | — | 11 Sep 2024 | |
| Geert Cauwenbergh |
3/4/5
|
Director |
—
class O/S missing
|
4,235
|
$6,395 | — | 17 Feb 2023 |
Institutional Holders of Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO) as of Q2 2025
As of 30 Jun 2025,
Phio Pharmaceuticals Corp. - Common Stock, $0.0001 par value per share (PHIO) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
164,722 shares.
The largest 10 holders included
GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Cetera Investment Advisers, Virtu Financial LLC, MORGAN STANLEY, Royal Bank of Canada, SBI Securities Co., Ltd., ASSETMARK, INC, BANK OF AMERICA CORP /DE/, and ELEVATION POINT WEALTH PARTNERS, LLC.
This page lists
11
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
10
Q2 2025 holders
11
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.